SEC Form 4 · accession 0001695028-26-000006
Oric Pharmaceuticals, Inc. · ORIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dominic Piscitelli
Officer — Chief Financial Officer
Period of report
Aug 26, 2026
Accepted (ET)
Aug 28, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001796280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 26, 2026 | M | 52,000 | $4.36 | A | 121,828 | D | |
| Common Stock | Aug 26, 2026 | M | 25,000 | $6.00 | A | 146,828 | D | |
| Common Stock | Aug 26, 2026 | S | 77,000 | $13.6859 | D | 69,828 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $4.36 | Aug 26, 2026 | M | 52,000 | D | Jul 20, 2025 | Jul 19, 2032 | Common Stock | 52,000 | 92,500 | D |
| Stock Option (right to buy)F3 | $6.00 | Aug 26, 2026 | M | 25,000 | D | — | Jan 31, 2033 | Common Stock | 25,000 | 120,000 | D |
Explanation of responses
- F1Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
- F2The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
- F325% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.